Dive into the Biopharma Space

Europe has rapidly become one of the world’s most dynamic regions for genetic analysis, sequencing technologies, and data-driven precision medicine. From liquid biopsies and transplant monitoring to next-generation bioinformatics platforms, a wave of innovative companies is redefining how genetic data is generated, interpreted, and applied in real clinical settings. At BiopharmIQ , we track 141 active European companies operating in genetic analysis, sequencing, and enablin

Seattle continues to make waves in the life sciences arena, blending the city’s deep research heritage with a new generation of biotech innovation. From next-generation antibody-drug conjugates to advanced RNA vaccines, the Emerald City is home to companies pushing the boundaries of how we diagnose, treat, and understand disease. Here are 10 companies to watch in 2025 , each driving fresh breakthroughs through clinical success, funding momentum, or technological innovation.

Southern California has long been known for its beaches and biotech, and nowhere is the region’s innovation more evident than in its antibody ecosystem . From San Diego’s wet labs  to Pasadena’s protein engineers , the area has become a proving ground for companies blending creativity, capital, and clinical progress. At BiopharmIQ, we’ve tracked more than a hundred SoCal bio/pharma's developing antibody-based drugs, and we’ve handpicked 10 companies to watch in 2025 , chosen

At BiopharmIQ , we’ve mapped over 280 biotech and pharma companies in Texas, tracking the rapid evolution of one of the most dynamic innovation hubs in the U.S. What once was a regional life sciences cluster is now a full-fledged ecosystem, where emerging bio/pharmas, mid-sized innovators, and major pharmaceutical players converge. This year’s landscape highlights clinical-stage activity, late preclinical acceleration, and significant capital infusions across therapeutic are

At BiopharmIQ , we’ve mapped 377 companies in the global AAV landscape . This work gave us a broad view of the ecosystem, from vector engineering innovators to clinical-stage pioneers and emerging players in new geographies. While big pharma has made major moves into AAV, this list focuses on bio/pharmas and mid-sized innovators  that stand out for their technology novelty, recent funding, promising clinical results, or regulatory momentum . Do you have them on your radar? 👁

Radiopharmaceuticals are rapidly gaining attention across the biopharma industry, combining targeted delivery with therapeutic...